OverviewSuggest Edit

Cyclerion Therapeutics is a biopharmaceutical company specializing in soluble guanylate cyclase (sGC) pharmacology. It discovers, develops and commercializes treatments for serious and orphan diseases. The company designs sGC stimulators with distinct pharmacologic and biodistribution properties that preferentially enhance nitric oxide-cGMP.
TypePublic
Founded2019
HQEly, GB
Websitecyclerion.com

Latest Updates

Employees (est.) (Nov 2020)94
Share Price (Nov 2020)$3
Cybersecurity ratingAMore

Key People/Management at Cyclerion

Andy Busch

Andy Busch

Chief Innovation Officer
Mark Currie

Mark Currie

President and Chief Scientific Officer
Christopher Wright

Christopher Wright

Chief Medical Officer
Craig Dunbar

Craig Dunbar

Vice President, Pharmaceutical Development
Peter Hecht

Peter Hecht

Chief Executive Officer, Director
William Huyett

William Huyett

Chief Financial Officer
Show more

Cyclerion Office Locations

Cyclerion has offices in Ely and Cambridge
Ely, GB (HQ)
Unit 3 Clive Ct
Cambridge, US
Rogers St & Fulkerson St
Show all (2)

Cyclerion Financials and Metrics

Cyclerion Revenue

Market capitalization (20-Nov-2020)

101.5m

Closing stock price (20-Nov-2020)

3.0
Cyclerion's current market capitalization is $101.5 m.
Show all financial metrics

Cyclerion Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Cyclerion Online and Social Media Presence

Embed Graph

Cyclerion News and Updates

Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects

Showed significant improvements in neurophysiological and objective performance measures associated with age-related cognitive decline and neurodegenerative diseases

Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease

Study results do not support further internal development Study results do not support further internal development

Cyclerion to Participate at Upcoming September 2020 Investor Conferences

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that Company mana…

Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

-  IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively   -

Cyclerion Therapeutics Presentation at Biomarkers in Alzheimer’s Disease Summit

CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today announced that Christopher Winrow, Ph.D., Senior Director, Neuroscience Development Program Lead,…

Cyclerion Frequently Asked Questions

  • When was Cyclerion founded?

    Cyclerion was founded in 2019.

  • Who are Cyclerion key executives?

    Cyclerion's key executives are Andy Busch, Mark Currie and Christopher Wright.

  • How many employees does Cyclerion have?

    Cyclerion has 94 employees.

  • Who are Cyclerion competitors?

    Competitors of Cyclerion include Ampio Pharmaceuticals, TG Therapeutics and Phio Pharmaceuticals.

  • Where is Cyclerion headquarters?

    Cyclerion headquarters is located at Unit 3 Clive Ct, Ely.

  • Where are Cyclerion offices?

    Cyclerion has offices in Ely and Cambridge.

  • How many offices does Cyclerion have?

    Cyclerion has 2 offices.